{"id":63032,"date":"2025-12-23T21:59:54","date_gmt":"2025-12-23T12:59:54","guid":{"rendered":"https:\/\/www.marketresearch.jp\/reports\/?p=63032"},"modified":"2026-09-25T13:07:54","modified_gmt":"2026-09-25T04:07:54","slug":"lutetium-177-market","status":"publish","type":"post","link":"https:\/\/www.marketresearch.jp\/reports\/lutetium-177-market\/","title":{"rendered":"\u4e16\u754c\u306e\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u88fd\u54c1\u30bf\u30a4\u30d7\u5225\uff08\u62c5\u4f53\u6dfb\u52a0\u30eb\u30c6\u30c1\u30a6\u30e0-177\u3001\u7121\u62c5\u4f53\u30eb\u30c6\u30c1\u30a6\u30e0-177\uff09\u3001\u88fd\u9020\u6280\u8853\u5225\uff08\u30b5\u30a4\u30af\u30ed\u30c8\u30ed\u30f3\u88fd\u9020\u3001\u539f\u5b50\u7089\u88fd\u9020\uff09\u3001\u7528\u9014\u5225\u3001\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u5225\u3001\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u5225 &#8211; \u30b0\u30ed\u30fc\u30d0\u30eb\u4e88\u6e2c2025-2032\u5e74"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.marketresearch.jp\/reports\/wp-content\/uploads\/2025\/12\/lutetium-177-statistics.png\" alt=\"Market Statistics\" style=\"max-width:100%;\"><\/p>\n<p>\u4ee5\u4e0b\u306b\u3001\u3054\u6307\u5b9a\u306e\u300cBasic TOC\u300d\u3068\u300cSegmentation Details\u300d\u3092\u7d44\u307f\u5408\u308f\u305b\u3066\u69cb\u7bc9\u3057\u305f\u8a73\u7d30\u306a\u76ee\u6b21\u3092\u65e5\u672c\u8a9e\u3067\u793a\u3057\u307e\u3059\u3002<\/p>\n<p>&#8212;<\/p>\n<p>**\u76ee\u6b21**<\/p>\n<p>**\u5e8f\u6587 (Preface)**<br \/>\n*   \u5e02\u5834\u30bb\u30b0\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u3068\u5bfe\u8c61\u7bc4\u56f2 (Market Segmentation &#038; Coverage)<br \/>\n*   \u8abf\u67fb\u5bfe\u8c61\u671f\u9593 (Years Considered for the Study)<br \/>\n*   \u901a\u8ca8 (Currency)<br \/>\n*   \u8a00\u8a9e (Language)<br \/>\n*   \u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc (Stakeholders)<br \/>\n**\u8abf\u67fb\u65b9\u6cd5 (Research Methodology)**<br \/>\n**\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u30b5\u30de\u30ea\u30fc (Executive Summary)**<br \/>\n**\u5e02\u5834\u6982\u8981 (Market Overview)**<br \/>\n**\u5e02\u5834\u30a4\u30f3\u30b5\u30a4\u30c8 (Market Insights)**<br \/>\n*   \u6cbb\u7642\u7d14\u5ea6\u30ec\u30d9\u30eb\u306e\u5411\u4e0a\u306b\u3088\u308b\u7121\u62c5\u4f53\u30eb\u30c6\u30c1\u30a6\u30e0-177\u306e\u63a1\u7528\u5897\u52a0 (Increasing adoption of no-carrier-added \u30eb\u30c6\u30c1\u30a6\u30e0-177 due to higher therapeutic purity levels)<br \/>\n*   \u524d\u7acb\u817a\u304c\u3093\u304a\u3088\u3073\u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d\u6cbb\u7642\u306b\u304a\u3051\u308b\u6a19\u7684\u653e\u5c04\u6027\u6838\u7a2e\u7642\u6cd5\u306e\u9700\u8981\u5897\u52a0 (Rising demand for targeted radionuclide therapies in prostate and neuroendocrine cancer treatment)<br \/>\n*   \u653e\u5c04\u6027\u533b\u85ac\u54c1\u5916\u6765\u8a3a\u7642\u30bb\u30f3\u30bf\u30fc\u306e\u62e1\u5927\u304c\u4e16\u754c\u7684\u306a\u5206\u6563\u578b\u6cbb\u7642\u30a2\u30af\u30bb\u30b9\u3092\u4fc3\u9032 (Expansion of radiopharmaceutical outpatient delivery centers driving decentralized treatment access globally)<br \/>\n*   \u30eb\u30c6\u30c1\u30a6\u30e0-177\u653e\u5c04\u6027\u540c\u4f4d\u4f53\u30b5\u30d7\u30e9\u30a4\u30c1\u30a7\u30fc\u30f3\u554f\u984c\u306e\u5b89\u5b9a\u5316\u306b\u5411\u3051\u305f\u539f\u5b50\u7089\u30a4\u30f3\u30d5\u30e9\u3078\u306e\u6295\u8cc7\u5897\u52a0 (Growing investments in reactor infrastructure to stabilize \u30eb\u30c6\u30c1\u30a6\u30e0-177 radioisotope supply chain issues)<br \/>\n*   \u524d\u7acb\u817a\u304c\u3093\u304a\u3088\u3073\u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d\u4ee5\u5916\u306e\u65b0\u305f\u306a\u816b\u760d\u9069\u5fdc\u75c7\u3092\u63a2\u7d22\u3059\u308b\u81e8\u5e8a\u8a66\u9a13\u306e\u6025\u5897 (Surge in clinical trials exploring new oncology indications beyond prostate and neuroendocrine tumors)<br \/>\n*   \u9577\u671f\u7684\u306a\u30eb\u30c6\u30c1\u30a6\u30e0-177\u4f9b\u7d66\u3092\u78ba\u4fdd\u3059\u308b\u305f\u3081\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3068\u540c\u4f4d\u4f53\u751f\u7523\u8005\u9593\u306e\u6226\u7565\u7684\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7 (Strategic partnerships between biotech firms and isotope producers to secure long-term \u30eb\u30c6\u30c1\u30a6\u30e0-177 supply)<br \/>\n*   \u30eb\u30c6\u30c1\u30a6\u30e0-177\u6cbb\u7642\u7528\u9014\u306b\u304a\u3044\u3066\u6700\u3082\u6025\u901f\u306b\u6210\u9577\u3059\u308b\u5730\u57df\u3068\u3057\u3066\u306eAPAC\u306e\u53f0\u982d (Emergence of Asia Pacific as the fastest-growing region for \u30eb\u30c6\u30c1\u30a6\u30e0-177 therapeutic applications)<br \/>\n*   \u6838\u533b\u5b66\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u304a\u3051\u308b\u8a3a\u65ad\u3068\u6cbb\u7642\u3092\u7d44\u307f\u5408\u308f\u305b\u305f\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u30a2\u30d7\u30ed\u30fc\u30c1\u3078\u306e\u79fb\u884c (Shift toward theranostic approaches combining diagnostics and therapeutics in nuclear medicine platforms)<br \/>\n*   \u65b0\u898f\u30eb\u30c6\u30c1\u30a6\u30e0-177\u30d9\u30fc\u30b9\u306e\u816b\u760d\u6cbb\u7642\u85ac\u306e\u8fc5\u901f\u627f\u8a8d\u3092\u652f\u63f4\u3059\u308b\u898f\u5236\u30a4\u30cb\u30b7\u30a2\u30c1\u30d6 (Regulatory initiatives supporting fast-track approvals for novel \u30eb\u30c6\u30c1\u30a6\u30e0-177 based oncology treatments)<br \/>\n*   \u751f\u7523\u52b9\u7387\u3068\u6bd4\u653e\u5c04\u80fd\u306e\u7d50\u679c\u3092\u5411\u4e0a\u3055\u305b\u308b\u540c\u4f4d\u4f53\u7cbe\u88fd\u6280\u8853\u306e\u9032\u6b69 (Advancements in isotope purification technologies enhancing production efficiency and specific activity outcomes)<br \/>\n**2025\u5e74\u7c73\u56fd\u95a2\u7a0e\u306e\u7d2f\u7a4d\u7684\u5f71\u97ff (Cumulative Impact of United States Tariffs 2025)**<br \/>\n**2025\u5e74\u4eba\u5de5\u77e5\u80fd\u306e\u7d2f\u7a4d\u7684\u5f71\u97ff (Cumulative Impact of Artificial Intelligence 2025)**<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u88fd\u54c1\u30bf\u30a4\u30d7\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Product Type)**<br \/>\n*   \u62c5\u4f53\u6dfb\u52a0\u30eb\u30c6\u30c1\u30a6\u30e0-177 (Carrier-Added \u30eb\u30c6\u30c1\u30a6\u30e0-177)<br \/>\n*   \u7121\u62c5\u4f53\u30eb\u30c6\u30c1\u30a6\u30e0-177 (No-Carrier-Added \u30eb\u30c6\u30c1\u30a6\u30e0-177)<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u751f\u7523\u6280\u8853\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Production Technology)**<br \/>\n*   \u30b5\u30a4\u30af\u30ed\u30c8\u30ed\u30f3\u30d9\u30fc\u30b9\u751f\u7523 (Cyclotron-Based Production)<br \/>\n*   \u539f\u5b50\u7089\u30d9\u30fc\u30b9\u751f\u7523 (Reactor-Based Production)<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u7528\u9014\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Application)**<br \/>\n*   \u7814\u7a76\u30fb\u524d\u81e8\u5e8a (Research &#038; Preclinical)<br \/>\n    *   In Vitro\u7814\u7a76 (In Vitro Studies)<br \/>\n    *   In Vivo\u52d5\u7269\u30e2\u30c7\u30eb (In Vivo Animal Models)<br \/>\n*   \u6cbb\u7642 (Therapeutics)<br \/>\n    *   \u8840\u6db2\u60aa\u6027\u816b\u760d (Hematologic Malignancies)<br \/>\n    *   \u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d (SSTR) (Neuroendocrine Tumors (SSTR))<br \/>\n    *   \u7de9\u548c\u7684\u9aa8\u8ee2\u79fb (Palliative Bone Metastases)<br \/>\n    *   \u524d\u7acb\u817a\u304c\u3093 (PSMA) (Prostate Cancer (PSMA))<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by End-User)**<br \/>\n*   \u75c5\u9662 (Hospitals)<br \/>\n*   \u5916\u6765\u8a3a\u7642\u30bb\u30f3\u30bf\u30fc (Outpatient Centers)<br \/>\n*   \u88fd\u85ac\u30fb\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d (Pharmaceutical and Biotechnology Companies)<br \/>\n*   \u7814\u7a76\u6a5f\u95a2 (Research Institutions)<br \/>\n*   \u5c02\u9580\u30af\u30ea\u30cb\u30c3\u30af (Specialty Clinics)<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Distribution Channel)**<br \/>\n*   \u76f4\u63a5\u8cfc\u5165 (Direct Purchase)<br \/>\n*   \u9593\u63a5 (Indirect)<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u5730\u57df\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Region)**<br \/>\n*   \u7c73\u5dde (Americas)<br \/>\n    *   \u5317\u7c73 (North America)<br \/>\n    *   \u4e2d\u5357\u7c73 (Latin America)<br \/>\n*   \u6b27\u5dde\u30fb\u4e2d\u6771\u30fb\u30a2\u30d5\u30ea\u30ab (Europe, Middle East &#038; Africa)<br \/>\n    *   \u6b27\u5dde (Europe)<br \/>\n    *   \u4e2d\u6771 (Middle East)<br \/>\n    *   \u30a2\u30d5\u30ea\u30ab (Africa)<br \/>\n*   \u30a2\u30b8\u30a2\u592a\u5e73\u6d0b (Asia-Pacific)<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u30b0\u30eb\u30fc\u30d7\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Group)**<br \/>\n*   ASEAN (ASEAN)<br \/>\n*   GCC (GCC)<br \/>\n*   \u6b27\u5dde\u9023\u5408 (European Union)<br \/>\n*   BRICS (BRICS)<br \/>\n*   G7 (G7)<br \/>\n*   NATO (NATO)<br \/>\n**\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\uff1a\u56fd\u5225 (\u30eb\u30c6\u30c1\u30a6\u30e0-177 Market, by Country)**<br \/>\n*   \u7c73\u56fd (United States)<br \/>\n*   \u30ab\u30ca\u30c0 (Canada)<br \/>\n*   \u30e1\u30ad\u30b7\u30b3 (Mexico)<br \/>\n*   \u30d6\u30e9\u30b8\u30eb (Brazil)<br \/>\n*   \u82f1\u56fd (United Kingdom)<br \/>\n*   \u30c9\u30a4\u30c4 (Germany)<br \/>\n*   \u30d5\u30e9\u30f3\u30b9 (France)<br \/>\n*   \u30ed\u30b7\u30a2 (Russia)<br \/>\n*   \u30a4\u30bf\u30ea\u30a2 (Italy)<br \/>\n*   \u30b9\u30da\u30a4\u30f3 (Spain)<br \/>\n*   \u4e2d\u56fd (China)<br \/>\n*   \u30a4\u30f3\u30c9 (India)<br \/>\n*   \u65e5\u672c (Japan)<br \/>\n*   \u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2 (Australia)<br \/>\n*   \u97d3\u56fd (South Korea)<br \/>\n**\u7af6\u4e89\u74b0\u5883 (Competitive Landscape)**<br \/>\n*   \u5e02\u5834\u30b7\u30a7\u30a2\u5206\u6790\u30012024\u5e74 (Market Share Analysis, 2024)<br \/>\n*   FPNV\u30dd\u30b8\u30b7\u30e7\u30cb\u30f3\u30b0\u30de\u30c8\u30ea\u30c3\u30af\u30b9\u30012024\u5e74 (FPNV Positioning Matrix, 2024)<br \/>\n*   \u7af6\u5408\u5206\u6790 (Competitive Analysis)<br \/>\n    *   ITM Isotope Technologies Munich SE<br \/>\n    *   Novartis AG<br \/>\n    *   Actinium Pharmaceuticals, Inc.<br \/>\n    *   Bayer AG<br \/>\n    *   BWX Technologies, Inc.<br \/>\n    *   Cardinal Health, Inc.<br \/>\n    *   China National Nuclear Corporation<br \/>\n    *   Curium Pharma<br \/>\n    *   Eckert &#038; Ziegler Radiopharma GmbH<br \/>\n    *   Framatome<br \/>\n    *   Fusion Pharmaceuticals Inc. by AstraZeneca<br \/>\n    *   IBA Radiopharma Solutions<br \/>\n    *   Isotopia Molecular Imaging Ltd.<br \/>\n    *   Lantheus Holdings, Inc.<br \/>\n    *   NorthStar Medical Radioisotopes, LLC<br \/>\n    *   NTP Radioisotopes SOC Ltd.<br \/>\n    *   Nuclear Research and Consultancy Group<br \/>\n    *   RadioMedix, Inc.<br \/>\n    *   RayzeBio, Inc. by Bristol Myers Squibb<br \/>\n    *   Revvity Inc.<br \/>\n    *   SHINE Technologies, LLC<br \/>\n    *   Telix Pharmaceuticals Limited<br \/>\n**\u56f3\u76ee\u6b21 [\u5408\u8a08: 30] (List of Figures [Total: 30])**<br \/>\n**\u8868\u76ee\u6b21 [\u5408\u8a08: 573] (List of Tables [Total: 573])**<\/p>\n<p>&#8230;&#8230;&#8230;&#8230; (\u4ee5\u4e0b\u7701\u7565)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u30eb\u30c6\u30c1\u30a6\u30e0-177\u5e02\u5834\u306f\u30012024\u5e74\u306b9\u51041,188\u4e07\u7c73\u30c9\u30eb\u3068\u8a55\u4fa1\u3055\u308c\u30012025\u5e74\u306b\u306f10\u51045,897\u4e07\u7c73\u30c9\u30eb\u306b\u9054\u3057\u30012032\u5e74\u307e\u3067\u306b31\u51043,445\u4e07\u7c73\u30c9\u30eb\u3078\u3068\u3001\u5e74\u5e73\u5747\u6210\u9577\u7387\uff08CAGR\uff0916.68%\u3067\u62e1\u5927\u3059\u308b\u3068\u4e88\u6e2c\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u30eb\u30c6\u30c1\u30a6\u30e0-177\u306f\u3001\u6a19\u7684\u653e\u5c04\u6027\u30ea\u30ac\u30f3\u30c9\u7642\u6cd5\u306b\u304a\u3044\u3066\u6975\u3081\u3066\u91cd\u8981\u306a\u653e\u5c04\u6027\u6838\u7a2e\u3068\u3057\u3066\u53f0\u982d\u3057\u3066\u304a\u308a\u3001\u81e8\u5e8a\u7814\u7a76\u8005\u3001\u88fd\u85ac\u958b\u767a\u8005\u3001\u5c02\u9580\u30b5\u30d7\u30e9\u30a4\u30c1\u30a7\u30fc\u30f3\u30d1\u30fc\u30c8\u30ca\u30fc\u304b\u3089\u306e\u95a2\u5fc3\u304c\u9ad8\u307e\u3063\u3066\u3044\u307e\u3059\u3002\u653e\u5c04\u7dda\u5316\u5b66\u3001\u6a19\u8b58\u6280\u8853\u3001\u30da\u30d7\u30c1\u30c9\u5de5\u5b66\u306b\u304a\u3051\u308b\u6700\u8fd1\u306e\u9032\u6b69\u306f\u3001\u30eb\u30c6\u30c1\u30a6\u30e0-177\u306e\u6cbb\u7642\u5fdc\u7528\u7bc4\u56f2\u3092\u65e2\u5b58\u306e\u9069\u5fdc\u75c7\u3092\u8d85\u3048\u3066\u62e1\u5927\u3055\u305b\u3066\u304a\u308a\u3001\u751f\u7523\u69d8\u5f0f\u3001\u898f\u5236\u7d4c\u8def\u3001\u81e8\u5e8a\u7d71\u5408\u3078\u306e\u65b0\u305f\u306a\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u5e02\u5834\u306f\u3001\u5b66\u8853\u30bb\u30f3\u30bf\u30fc\u3001\u533b\u85ac\u54c1\u53d7\u8a17\u88fd\u9020\u958b\u767a\u6a5f\u95a2\uff08CDMO\uff09\u3001\u5c02\u9580\u306e\u653e\u5c04\u7dda\u85ac\u5c40\u304c\u9023\u643a\u3057\u3001\u524d\u81e8\u5e8a\u6bb5\u968e\u306e\u6709\u671b\u306a\u6210\u679c\u3092\u65e5\u5e38\u7684\u306a\u6cbb\u7642\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u3078\u3068\u5909\u63db\u3059\u308b\u30c0\u30a4\u30ca\u30df\u30c3\u30af\u306a\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u3092\u5f62\u6210\u3057\u3066\u304a\u308a\u3001\u6280\u8853\u7684\u6d17\u7df4\u3068\u81e8\u5e8a\u9700\u8981\u306e\u76f8\u4e92\u4f5c\u7528\u304c\u73fe\u5728\u306e\u79d1\u5b66\u7684\u52e2\u3044\u3092\u5f62\u6210\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u5e02\u5834\u306f\u3001\u88fd\u54c1\u30bf\u30a4\u30d7\u3001\u751f\u7523\u6280\u8853\u3001\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3001\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u3001\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u3068\u3044\u3063\u305f\u591a\u89d2\u7684\u306a\u30ec\u30f3\u30ba\u3092\u901a\u3057\u3066\u8a73\u7d30\u306b\u30bb\u30b0\u30e1\u30f3\u30c8\u5316\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts\/63032"}],"collection":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/comments?post=63032"}],"version-history":[{"count":2,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts\/63032\/revisions"}],"predecessor-version":[{"id":63553,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts\/63032\/revisions\/63553"}],"wp:attachment":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/media?parent=63032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/categories?post=63032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/tags?post=63032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}